MedTrace Logo

Patient Registry of Intrathecal Ziconotide Management(PRIZM)

NCT01888120 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2017-03-16

No results posted yet for this study

Summary

The objectives of this study are to evaluate the effectiveness, long-term safety, tolerability, satisfaction with treatment, and health-related quality of life (HRQoL) associated with Intrathecal PRIALT use for severe chronic pain of varying etiologies.

Conditions

  • Patients With Severe Chronic Pain

Interventions

DRUG

Ziconotide

Sponsors & Collaborators

Principal Investigators

  • I-Zu Huang, MD · Jazz Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2017-01-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01888120 on ClinicalTrials.gov